Ovarian cancer genetic testing is underused and large gene panels lead to uncertain results, particularly for non-white patients, a Stanford Medicine study finds.
In the burgeoning field of pharmacogenetics, adhering to expert-developed guidelines is increasingly important, a Stanford Medicine physician emphasizes.
The prevalence of genetic testing in the United States falls short of the recommended guidelines for women with ovarian cancer, new research indicates.
Online outreach and low-cost testing can encourage relatives of cancer patients to assess their own cancer risk through 'cascade' testing.
Stanford researchers use gene editing and stem cell technologies to determine whether to worry — or not — about mysterious genetic test results.
Women with breast cancer are increasingly receiving multigene genetic testing rather than just screening for the BRCA mutations, new research suggests.
Stanford’s Cancer Genetics Program helps assess families' hereditary cancer risks and guide patients to make informed choices about prevention and treatment.